1/16/2020 7:36:44 AM
TG Therapeutics Initiates Rolling Submission Of NDA To FDA For Umbralisib
9/12/2019 7:35:41 AM
TG Therapeutics Presents Data For Ublituximab At The 35th Annual Congress Of ECTRIMS
6/17/2019 7:50:18 AM
TG Therapeutics Announces Presentation Of Preclinical Data For TG-1801
6/17/2019 7:38:39 AM
TG Therapeutics Presents Preclinical Data For TG-1801 At EHA
6/11/2019 7:59:55 AM
TG Therapeutics Confirms Registration Path For Umbralisib Following FDA Meeting
2/26/2019 7:45:14 AM
TG Therapeutics Begins Phase I First-in-Human Clinical Trial Of TG-1801
1/22/2019 7:32:14 AM
TG Therapeutics Receives Breakthrough Therapy Designation From TFDA For Umbralisib For Marginal Zone Lymphoma
12/4/2018 7:34:02 AM
TG Announces Data From Triple Combination Of Ublituximab, Umbralisib, Bendamustine In Patients With DLBCL And FL
12/3/2018 7:49:07 AM
TG Announces Oral Presentation Of Follow-Up Data From Triple Combination Of Ublituximab, Umbralisib, And Pembrolizumab
11/9/2018 7:33:53 AM
TG Therapeutics Q3 Net Loss $34.0 Mln Vs Net Loss $31.5 Mln Last Year
9/26/2018 8:48:41 AM
Jefferies Is Cutting TG Therapeutics Inc. (TGTX) FY20 Estimate To -2.35 From -1.69
9/26/2018 8:48:25 AM
Jefferies Is Lowering TG Therapeutics Inc. (TGTX) FY19 Estimate To -1.98 From -1.88
9/26/2018 8:48:03 AM
Jefferies Is Lowering TG Therapeutics Inc. (TGTX) FY18 Estimate To -2.20 From -2.10
8/7/2018 7:34:33 AM
TG Therapeutics Completes Target Enrollment In ULTIMATE Phase 3 Trials In Multiple Sclerosis
6/20/2018 7:33:29 AM
TG , Novimmune Announce Deal For Development And Commercialization Of Novel Anti-CD47/ Anti-CD19 Bispecific Antibody